Welcome to our dedicated page for Zymergen news (Ticker: ZY), a resource for investors and traders seeking the latest updates and insights on Zymergen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zymergen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zymergen's position in the market.
On May 24, 2021, Zymergen reported preliminary financial results for Q1 2021, highlighting a total revenue of $3.7 million, a 26% increase year-over-year. This growth was driven by R&D services and collaboration revenue. Operating expenses rose to $87.1 million, a 32.8% increase, primarily due to heightened R&D activities and costs related to its IPO. The net loss for the quarter was $84.6 million, with cash reserves at $121 million as of March 31, 2021. Zymergen successfully raised approximately $530 million in net proceeds from its IPO in April 2021.
Zymergen, a leader in biofacturing, will participate in the UBS Global Healthcare Virtual Conference on May 26, 2021. The presentation is scheduled for 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested stakeholders can access a live and archived webcast through the Investors' section of the company's website. Zymergen focuses on designing and manufacturing bio-based products across diverse industries, leveraging a unique blend of biology, chemistry, software, and automation.
Zymergen, a leader in biofacturing, will release its financial results for Q1 2021 on May 24, 2021. Management will discuss the results along with business developments and outlook during a conference call at 1:30 PM PT. The call can be accessed via a webcast, which will be available for replay for 90 days. Zymergen specializes in using biology to create innovative bio-based products across various industries through a unique integration of biology, chemistry, software, and automation.
Zymergen has successfully closed its initial public offering (IPO) of 18,549,500 shares at a price of $31.00 each, raising approximately $575 million in gross proceeds. The underwriters exercised their option to purchase an additional 2,419,500 shares. The shares are now listed on the Nasdaq under the ticker symbol 'ZY'. J.P. Morgan and Goldman Sachs are the lead book-running managers for this offering. Zymergen specializes in biofacturing, using advanced technology to produce bio-based products across various industries.
Zymergen has priced its initial public offering (IPO) at $31.00 per share, offering 16,130,000 shares. The underwriters have a 30-day option to acquire an additional 2,419,500 shares. The total expected gross proceeds to the company are approximately $500 million, excluding any exercise of the underwriters’ option. Zymergen's common stock is set to trade on the Nasdaq under the ticker 'ZY' starting April 22, 2021, with the offering closing on April 26, 2021, pending customary conditions.
Zymergen Inc. has initiated the roadshow for its initial public offering (IPO) of 13,600,000 shares, priced between $28 and $31 per share. An additional 2,040,000 shares may be purchased by underwriters within 30 days. The company has applied to list its common stock on the Nasdaq under the symbol 'ZY.' J.P. Morgan and Goldman Sachs are the lead managers for the offering. A registration statement is filed with the U.S. SEC, but securities cannot be sold until it becomes effective.